XBiotech Inc.
XBIT
|
$7.98
0.89%
0.88%
76K
|
Health Technology
(0.0% 1d) (10.9% 1m) (132.4% 1y) (0.0% 2d) (-0.9% 3d) (-14.6% 7d) (-6.92% volume)
Earnings Calendar:
Market Cap: $ 242,998,030
http://www.xbiotech.com
Sec Filling | Patents | 60 employees
(US) XBiotech, Inc. is a biopharmaceutical company. The firm engages in the development and commercialization of therapeutic antibodies. Its product pipeline includes oncology, infectious diseases, dermatology and inflammatory disorders. The company was founded by John Simard on March 22, 2005 and is headquartered in Austin, TX.
antibody infectious disease
add to watch list Paper trade email alert is off
Press-releases
XBiotech to Begin Constructing New R&D Facility on its 48-acre Campus
Published: 2024-01-04 (Crawled : 14:00) - globenewswire.com
XBIT | $7.98 0.89% 0.88% 76K
|
Health Technology
|
| O: 0.23%
H: 0.0%
C: -1.4%
Dr. Alan Kivitz to Chair XBiotech’s Natrunix Program in Rheumatoid Arthritis
Published: 2023-11-14 (Crawled : 14:30) - globenewswire.com
XBIT | $7.98 0.89% 0.88% 76K
|
Health Technology
|
| O: 1.02%
H: 2.27%
C: -4.03%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 0.68%
H: 0.0%
C: 0.0%
program
XBiotech Announces Enrollment Completion of Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for Stroke
Published: 2023-09-26 (Crawled : 13:00) - globenewswire.com
XBIT | $7.98 0.89% 0.88% 76K
|
Health Technology
|
| O: -0.72%
H: 1.33%
C: 0.24%
candidate stroke trial therapy
XBiotech Announces Enrollment Completion of Phase II, Placebo Controlled, Multicenter Study for Natrunix in Pancreatic Cancer
Published: 2023-08-30 (Crawled : 13:00) - globenewswire.com
XBIT | $7.98 0.89% 0.88% 76K
|
Health Technology
|
| O: -0.39%
H: 0.39%
C: -2.92%
cancer pancreatic study
XBiotech Announces First Patient Begins Novel Natrunix Therapy in Phase II Rheumatoid Arthritis (RA) Clinical Trial
Published: 2023-08-08 (Crawled : 15:20) - globenewswire.com
XBIT | $7.98 0.89% 0.88% 76K
|
Health Technology
|
| O: 1.02%
H: 3.43%
C: 0.81%
trial therapy
FDA Authorizes Phase II Study for Natrunix in Rheumatoid Arthritis Patients
Published: 2023-05-22 (Crawled : 13:00) - globenewswire.com
XBIT | $7.98 0.89% 0.88% 76K
|
Health Technology
|
| O: -0.4%
H: 5.58%
C: 2.43%
fda study
FDA Authorizes Phase II Study for Natrunix in Rheumatoid Arthritis PatientsXBiotech Believes its Drug Candidate Natrunix Could Revolutionize Arthritis Treatment
Published: 2023-05-22 (Crawled : 20:00) - biospace.com/
XBIT | $7.98 0.89% 0.88% 76K
|
Health Technology
|
| O: -0.4%
H: 5.58%
C: 2.43%
fda drug candidate treatment study
XBiotech Commences Tender Offer to Purchase up to $80,000,000 Worth of Its Shares
Published: 2023-05-17 (Crawled : 13:00) - globenewswire.com
XBIT | $7.98 0.89% 0.88% 76K
|
Health Technology
|
| O: 14.08%
H: 19.37%
C: 13.1%
XBiotech Announces First Subject Enrollment in Phase I Clinical Trial for Hutrukin, a Novel Candidate Therapy for StrokeHutrukin, A Therapy Discovered and Manufactured at XBiotech, Is Aimed to Reduce Brain Injury after Stroke
Published: 2023-04-17 (Crawled : 14:20) - biospace.com/
XBIT | $7.98 0.89% 0.88% 76K
|
Health Technology
|
| O: 4.49%
H: 0.23%
C: -1.08%
candidate stroke trial therapy
Acne Drugs Market size to grow by USD 907.11 million from 2022 to 2027, Driven by the emergence of improved diagnostic modalities - Technavio
Published: 2023-04-14 (Crawled : 04:00) - prnewswire.com
DERM | $3.45 -3.63% -3.77% 100K
|
|
| O: -8.54%
H: 2.0%
C: 0.0%
RBGPF | $51.61 6.46% 4.7K
|
Consumer Non-Durables
|
| O: -1.42%
H: 0.0%
C: -0.22%
GLAXF | News | $20.2 -14.18% 510
|
Health Technology
|
| O: 0.94%
H: 0.0%
C: -0.93%
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: 1.98%
H: 0.0%
C: -0.6%
RBGLY | $10.35 -2.05% 990K
|
Manufacturing
|
| O: -0.35%
H: 0.33%
C: 0.13%
VTRS A | $11.25 1.17% 1.16% 4.7M
|
Health Technology
|
| O: -0.2%
H: 0.51%
C: -0.3%
GSK | News | $39.75 1.22% 0.0% 1.6M
|
Health Technology
|
| O: -0.57%
H: 0.04%
C: -0.87%
XBIT | $7.98 0.89% 0.88% 76K
|
Health Technology
|
| O: -0.83%
H: 1.95%
C: -0.84%
diagnostic acne market
Last 15 days Sec forms
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 67% | 33% |
Top 10 Gainers
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
GBR | $1.42 31.48% 11.27% 990K
|
Energy Minerals
DEO | News | $140.76 -0.02% 8.27% 560K
|
Consumer Non-Durables
KUKE | $2.88 2.49% 7.64% 360K
|
SYY | $76.73 1.44% 5.49% 2.5M
|
Distribution Services
TWI | $11.53 0.96% 4.94% 330K
|
Producer Manufacturing
BTCM | $1.99 -6.13% 4.52% 75K
|
Arts, Entertainment, and Recrea...
MPLN | $0.6502 -11.74% 4.51% 2.2M
|
Finance
CXM 4 | $11.34 -0.44% 4.27% 1.7M
|
Information
UHS | $157.47 2.49% 4.13% 900K
|
Health Services
Last 48 Hours Insiders Buying
RXO P 200000 | $19.37 2.32% 0.0% 1M
|
n/a
|
23:00
RKT P 380 | $11.68 1.3% 0.17% 1.9M
|
Finance
|
22:30
HROW P 29400 | $10.43 -3.87% -4.03% 680K
|
Health Technology
|
22:30
BCDA P 2750 | $0.377 -1.4% 97K
|
Health Technology
|
22:00
RMCF | $3.67 3.38% 3.27% 11K
|
Consumer Non-Durables
|
20:10